Fortress Biotech Inc (FBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fortress Biotech Inc (FBIO) has a cash flow conversion efficiency ratio of -0.202x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.54 Million) by net assets ($62.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Fortress Biotech Inc balance sheet quality to measure how much of total assets are equity-financed.
Fortress Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Fortress Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Fortress Biotech Inc (FBIO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Fortress Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fortress Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sical Logistics Limited
NSE:SICALLOG
|
N/A |
|
Azaria Rental SOCIMI S.A.
MC:YAZR
|
-0.025x |
|
Life Settlement Assets PLC
LSE:LSAA
|
0.123x |
|
Act Co Ltd
KQ:138360
|
-0.024x |
|
EverFocus Electronics Corp
TW:5484
|
-0.043x |
|
Vera Bradley Inc
NASDAQ:VRA
|
-0.042x |
|
Tasco Bhd
KLSE:5140
|
-0.035x |
|
VIVANI MED.INC. NEW O.N.
F:U5P
|
-0.427x |
Annual Cash Flow Conversion Efficiency for Fortress Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Fortress Biotech Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see FBIO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $62.18 Million | $-65.78 Million | -1.058x | -102.17% |
| 2024-12-31 | $-1.64 Million | $-80.19 Million | 48.778x | +160.37% |
| 2023-12-31 | $1.59 Million | $-128.22 Million | -80.797x | -2152.98% |
| 2022-12-31 | $50.02 Million | $-179.40 Million | -3.586x | -595.08% |
| 2021-12-31 | $225.88 Million | $-116.54 Million | -0.516x | -21.46% |
| 2020-12-31 | $197.00 Million | $-83.68 Million | -0.425x | +67.55% |
| 2019-12-31 | $72.53 Million | $-94.96 Million | -1.309x | +73.85% |
| 2018-12-31 | $19.74 Million | $-98.85 Million | -5.007x | -606.22% |
| 2017-12-31 | $120.50 Million | $-85.43 Million | -0.709x | -28.39% |
| 2016-12-31 | $82.97 Million | $-45.81 Million | -0.552x | -128.35% |
| 2015-12-31 | $84.27 Million | $-20.38 Million | -0.242x | -4.40% |
| 2014-12-31 | $70.52 Million | $-16.33 Million | -0.232x | +36.50% |
| 2013-12-31 | $81.28 Million | $-29.65 Million | -0.365x | +65.35% |
| 2012-12-31 | $22.03 Million | $-23.19 Million | -1.053x | -83.89% |
| 2011-12-31 | $19.13 Million | $-10.95 Million | -0.572x | -34.92% |
| 2010-12-31 | $13.38 Million | $-5.68 Million | -0.424x | -282.10% |
| 2009-12-31 | $-10.09 Million | $-2.35 Million | 0.233x | -- |
About Fortress Biotech Inc
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalc… Read more